Natus Medical (NASDAQ:BABY) announced its quarterly earnings results on Wednesday. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by ($0.12), Bloomberg Earnings reports. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business had revenue of $131.40 million for the quarter, compared to analyst estimates of $131.38 million. During the same period in the prior year, the business earned $0.51 EPS. The company’s revenue for the quarter was up 22.0% compared to the same quarter last year. Natus Medical updated its Q1 guidance to $0.23-0.24 EPS.
Natus Medical (NASDAQ:BABY) opened at $30.80 on Thursday. The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $959.55, a price-to-earnings ratio of -513.33 and a beta of 0.56. Natus Medical has a 12-month low of $28.00 and a 12-month high of $43.60.
In other Natus Medical news, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by company insiders.
Several equities research analysts have issued reports on the company. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Tuesday, October 24th. BidaskClub downgraded Natus Medical from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. William Blair downgraded Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Benchmark reaffirmed a “buy” rating and set a $49.00 price target (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. Natus Medical presently has a consensus rating of “Hold” and a consensus price target of $47.00.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.